Patent
Compounds for the treatment of inflammatory disorders
| العنوان: | Compounds for the treatment of inflammatory disorders |
|---|---|
| Patent Number: | 8,541,572 |
| تاريخ النشر: | September 24, 2013 |
| Appl. No: | 13/127952 |
| Application Filed: | November 09, 2009 |
| مستخلص: | This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF—or combinations thereof. [chemical expression included] |
| Inventors: | Kozlowski, Joseph A. (Princeton, NJ, US); Yu, Wensheng (Edison, NJ, US); Wong, Michael K. C. (Somerset, NJ, US); Kim, Seong Heon (Livington, NJ, US); Tong, Ling (Warren, NJ, US); Lavey, Brian J. (New Providence, NJ, US); Shankar, Bandarpalle B. (Branchburg, NJ, US); Yang, De-Yi (Morris Plains, NJ, US); Feltz, Robert (Washington, PA, US); Kosinski, Aneta Maria (South Amboy, NJ, US); Zhou, Guowei (Somerset, NJ, US); Rizvi, Razia K. (Bloomfield, NJ, US); Dai, Chaoyang (Acton, MA, US); Fire, Luke (Cambridge, MA, US); Girijavallabhan, Vinay (Denville, NJ, US); Li, Dansu (Reading, MA, US); Popovici-Muller, Janeta (Waltham, MA, US); Richard, Judson E. (Kittery, ME, US); Rosner, Kristin E. (Watertown, MA, US); Siddiqui, M. Arshad (Newton, MA, US); Yang, Liping (Arlington, MA, US) |
| Assignees: | Merck Sharp & Dohme Corp. (Rahway, NJ, US) |
| Claim: | 1. A compound selected from the group consisting of [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] and a pharmaceutically acceptable salt thereof. |
| Claim: | 2. The compound of claim 1 , selected from the group consisting of: [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] [chemical expression included] and a pharmaceutically acceptable salt thereof. |
| Claim: | 3. The compound of claim 2 , selected from the group consisting of: [chemical expression included] and a pharmaceutically acceptable salt thereof. |
| Claim: | 4. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. |
| Current U.S. Class: | 544/59 |
| Patent References Cited: | 6495565 December 2002 Duan et al. 6534491 March 2003 Levin et al. 6677355 January 2004 Conrad et al. 7041693 May 2006 Sheppeck 7482370 January 2009 Yu et al. 7488745 February 2009 Yu et al. 7504424 March 2009 Yu et al. 7524842 April 2009 Lavey et al. 7683085 March 2010 Yu et al. 7683088 March 2010 Lavey et al. 7687527 March 2010 Yu et al. 7772263 August 2010 Lavey et al. 7879890 February 2011 Yu et al. 7998961 August 2011 Mansoor et al. 8178553 May 2012 Lavey et al. 2007/0219218 September 2007 Yu et al. 2011/0288054 November 2011 Shankar et al. 2011/0288077 November 2011 Wong et al. 2012/0015926 January 2012 Tong et al. WO02/074750 September 2002 WO02/096426 December 2002 WO03/053940 July 2003 WO03/053941 July 2003 WO2004/012663 February 2004 WO2004/024698 March 2004 WO2004/024715 March 2004 WO2004/024721 March 2004 WO2004/056766 July 2004 WO2006/019768 February 2006 WO2007/084451 July 2007 |
| Other References: | Moss, M. L., Sklair-Tavron, L.,Nudelman, R. Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nature Clinical Practice Rheumatology. Apr. 4, 2008. 300-309. cited by examiner Shafer, S., Kolkhof, P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discovery Today. Nov. 13, 2008, 913-916. cited by examiner Horig, H., Pullman, W. From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference. Journal of Translational Medicine. Dec. 2, 2004, 44. cited by examiner Girijavallabhan et al. Novel TNF-alpha converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases. Bioorganic & Medicinal Chemistry Letter. Oct. 20, 2010, 7283-7287. cited by examiner PCT International Search Report dated May 19, 2011 corresponding to PCT Application No. PCT/US2009/063670. cited by applicant Knaggs, A., et al., “Biotransformation of Alosetron: Mechanism of Hydantoin Formation”, Tetrahedron Letters, vol. 36, No. 3, pp. 477-480 (1995). cited by applicant |
| Assistant Examiner: | Chen, Po-Chih |
| Primary Examiner: | Nolan, Jason M |
| Attorney, Agent or Firm: | Meade, Eric A. Camara, Valerie J. |
| رقم الانضمام: | edspgr.08541572 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |